Optometric Management

FEB 2017

Issue link: http://optometricmanagement.epubxp.com/i/781116

Contents of this Issue


Page 36 of 64

34 F E B R U A R Y 2 0 1 7 • O P T O M E T R I C M A N A G E M E N T . C O M CLINICAL DRY EYE W HICH CAME first, the chicken or the egg? It's an age-old question yet to be answered. Similarly, O.D.s oen debate whether inflamma- tion or obstruction comes first in meibomian gland dysfunction (MGD). e question isn't linear, and neither is the answer. INFLAMMATION Traditionally, inflammation (aka the chicken) was considered the root cause of dry eye disease (DED) patients' suffering, regard- less of whether it was aqueous de- ficient or evaporative. Once palliative care, such as artificial tears, failed to resolve signs and/or symptoms, anti- inflammatory topical and oral drugs were employed. For exam- ple, steroid drops, despite increas- ing IOP, decrease inflammation. Cyclosporine ophthalmic emul- sion 0.05% (Restasis, Allergan), an immunosuppressive compound, provides relief for many chronic DED patients without the risks of long-term steroid use. Also, some doctors report successfully quiet- ing inflammation via the off-label use of ophthalmic azithromycin (AzaSite, Akorn). Meanwhile, oral therapeutics, such as doxycycline and minocycline can treat inflama- tion in MGD, ocular rosacea and corneal wound healing. OBSTRUCTION When it was established that 86% of DED was evaporative (aka the egg) in nature, the pendulum swung toward the management of obstruction (See tinyurl.com/ EvapDED). While most eye care providers didn't abandon anti-inflammatory drugs, emerging treatment options (thermal pulsation, punctal prob- ing and intense pulse light) trended toward the management of impact- ed glands to avoid meibomian gland dilation and atrophy. e argument for early intervention and aggressive treatment makes sense: If glands are congested with inspissated meibum, logic (and published research) dictates that patients find relief through evacuation. IT'S NOT ONE OR THE OTHER Some O.D.s view this treatment decision as one or the other. With the advent of new DED drugs, such as lifitegrast ophthalmic solution 5% (Xiidra, Shire), many O.D.s are experiencing a "reawakening" to the inflammatory origin of DED. However, the pendulum needn't swing back the other direction: If doctors truly subscribe to the circular nature of DED, both in- flammation and obstruction may require evaluation and treatment. Further, doctors now have at their fingertips a variety of tests to help isolate the influence of each. LET'S REJECT THE QUESTION Maybe the theoretical construct that either the chicken or the egg came first should be discarded. It's conceivable that the two arrived on the scene at virtually the same time. Perhaps one opened the door for the other or created a hospitable environment, allowing its coun- terpart to thrive. Inflammation and obstruction are also likely to be intertwined and inseparable in the treatment of evaporative DED. Case closed. OM WHICH COMES FIRST ? BOTH INFLAMMATION AND OBSTRUCTION REQUIRE YOUR ATTENTION WHITNEY HAUSER, O.D. DR. HAUSER provides clinical care for pa- tients at TearWell: Advance Dry Eye Treatment Center and the Advanced Care and The Eye Center at Southern College of Optom- etry. She is a consultant, speaker or board member for: Akorn, Alcon, Al- lergan, BioTeck, BioTissue, Lumenis, NovaBay, Paragon Vision Sciences, Rysurg, TearLab, TearScience, Shire, Science Based Health and DryEye- Coach.com. To comment, visit tinyurl. com/OMComment.

Articles in this issue

Links on this page

Archives of this issue

view archives of Optometric Management - FEB 2017